BrightPath Biotherapeutics Co., Ltd

Looking for a EU partner for licensing agreement

KEY ACTIVITIESDrug and drug discovery
KEY WORDS:Cancer cell, Immuno-modulatory antibody

Company Activity Description:

BrightPath Biotherapeutics is a Japan-based clinical-stage biopharmaceutical company focused on research and development of novel cancer immunotherapeutics. The company pipeline includes cancer peptide vaccine, rejuvenated T-cell therapy, and immuno-modulator antibodies.


BrightPath Biotherapeutics is also conducting research and development regarding cancer neoantigen.


Type of Partnership Sought:

1.License agreement


Additional information:

BrightPath Biotherapeutics is aiming to license its latest researches.

# Out-license of GRN-1201 and GRN-1301

# In-license/collaboration of research or early-stage clinical programs and related technologies regarding;

   - Cancer cell therapy

   - Immuno-modulatory antibody

   - Cancer neoantigen

Products & ServiceStageOutline
1) GRN-1201Phase 2 in combination with immuno-checkpoint inhibitor  (Indication: NSCLC)A cancer peptide vaccine comprising four peptide antigens
2) GRN-1301Basic research (Indication: NSCLC)A cancer neoantigen peptide vaccine targeting non-small cell lung cancer with EGFR-T790M point mutation
3) iPS-T cell therapyBasic research (Indication: Lymphoma)Induced pluripotent stem cell (iPSC)-derived, rejuvenated T cell therapy


Link to Full detail of the presentation

Company website

Success stories

Latest success stories of EU and Japanese companies supported by the EU-Japan Centre

Read more

Contact us

EU SMEs looking for partners in Japan can contact us and register to our newsletter to be kept informed bout our activities.

Contact us